Clyburn Issues Statement on Authorization of Moderna, Pfizer-BioNTech Bivalent Coronavirus Boosters

Aug 31, 2022
Press Release

Washington, D.C. (August 31, 2022) – Today, Rep. James E. Clyburn, Chairman of the Select Subcommittee on the Coronavirus Crisis, issued the following statement after the Food and Drug Administration’s (FDA) authorized Moderna and Pfizer-BioNTech single dose bivalent coronavirus vaccines for use as a booster at least two months following primary or booster vaccination.

“FDA’s authorization of two bivalent coronavirus boosters will provide Americans an additional layer of protection against severe outcomes from COVID-19 and the Omicron BA.4 and BA.5 subvariants.  This decision marks a significant development in our nation’s ability to adapt to and protect ourselves against current and emerging strains of the coronavirus.  I commend the scientists who have worked diligently and expeditiously to ensure Americans have immediate access to updated versions of the safe, effective coronavirus vaccines.  As the Biden-Harris Administration prepares to distribute these vaccines, I urge Americans to have themselves and their loved ones vaccinated and boosted as soon as they are eligible.”

117th Congress